WP
TSHA icon

Woodline Partners’s Taysha Gene Therapies TSHA Stock Holding History

Woodline Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.5M Hold
513,828
– – 0.01% 767
2026
Q1 		$2.3M Buy
513,828
+13,828
+3% +$64.3K 0.01% 791
2025
Q4 		$2.75M Hold
500,000
– – 0.01% 733
2025
Q3 		$1.64M Sell
500,000
-500,254
-50% -$1.42M 0.01% 749
2025
Q2 		$2.31M Buy
1,000,254
+142,000
+17% +$309K 0.01% 702
2025
Q1 		$1.19M Sell
858,254
-169,268
-16% -$283K 0.01% 745
2024
Q4 		$1.78M Buy
1,027,522
+28
+0% +$58 0.01% 670
2024
Q3 		$2.07M Buy
1,027,494
+1,225
+0.1% +$2.69K 0.02% 475
2024
Q2 		$2.3M Buy
+1,026,269
New +$2.99M 0.02% 409

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's TSHA Position: Q2 2026 in Review

Woodline Partners held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 513,828 shares worth $3.5M. The position accounts for 0.01% of the portfolio, ranked #767.

Woodline Partners first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Woodline Partners held 513,828 shares of Taysha Gene Therapies worth $3.5M as of Q2 2026.
  • Woodline Partners left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #767 holding.
  • Woodline Partners first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.